SHELTON,
Conn., May 15, 2024 /PRNewswire/
-- Intensity Therapeutics, Inc. ("Intensity" or "the
Company") (Nasdaq: INTS), a late-stage clinical biotechnology
company focused on the discovery and development of proprietary,
novel immune-based intratumoral cancer therapies designed to kill
tumors and increase immune system recognition of cancers, announces
the appointment of Thomas Dubin,
J.D., MPH, to the Intensity Board of Directors, effective
May 14, 2024. Mr. Dubin will
serve as a member of the Audit Committee of the Board. In
connection with Mr. Dubin's appointment, the size of the Board was
increased from four directors to five. Of these five directors,
four are independent pursuant to Nasdaq standards.
"We are pleased to welcome Tom
Dubin to the Intensity Board," said Lewis H. Bender, Founder, Chairman, and CEO of
Intensity Therapeutics, Inc. "As we prepare to enter Phase 3
clinical development with our unique product candidate, INT230-6,
we expect that Tom's deep experience in pharmaceutical business
development, regulatory, and commercialization will be invaluable.
We believe that Tom's commitment to patients, focus on achievement
and past successes will strengthen Intensity in multiple ways. We
look forward to working with him as we continue our path forward
with our exciting new cancer treatment approach."
From 2001 through 2013, Thomas
Dubin was the chief legal officer and a member of the core
executive team that grew Alexion Pharmaceuticals from a
development-stage company to a member of the S&P 500. At
Alexion, Tom led legal and government affairs, pricing and
reimbursement, corporate communications, and other functions. He
also held commercial responsibility for the company's Australasia
region. Before Alexion, Tom served as Vice President and
General Counsel of ChiRex, Inc., an international corporation
providing advanced process development services and specialty
manufacturing to the pharmaceutical industry. Tom began his career
as a corporate attorney with Cravath, Swaine & Moore in
New York City. He is Chair of
Cellphire Therapeutics, a Director of Notable Laboratories, past
Director of BioBlast Pharmaceuticals, member of the advisory board
of Mythic Pharmaceuticals, Director of Norwalk Hospital, and a
member of Yale School of Public
Health's Leadership Council. He received his J.D. from
New York University School of Law, his
M.P.H. from Yale University and his
B.A. from Amherst College, cum
laude.
About INT230-6
INT230-6, Intensity's lead proprietary
investigational product candidate, is designed for direct
intratumoral injection. INT230-6 was discovered using Intensity's
proprietary DfuseRx℠ technology platform. The drug is composed of
two proven, potent anti-cancer agents, cisplatin and vinblastine,
and a penetration enhancer molecule (SHAO) that helps disperse
potent cytotoxic drugs throughout tumors for diffusion into cancer
cells. These agents remain in the tumor resulting in a favorable
safety profile. In addition to local disease control, direct
killing of the tumor by INT230-6 releases a bolus of neoantigens
specific to the patient's malignancy, leading to engagement of the
immune system and systemic anti-tumor effects. Importantly, these
effects are mediated without immunosuppression that so often occurs
with systemic chemotherapy.
About Intensity Therapeutics
Intensity Therapeutics is
a late-stage clinical biotechnology company that applies novel
engineered chemistry to turn "cold" tumors "hot" by enabling its
aqueous cytotoxic-containing drug product, INT230-6, to mix and
saturate the dense, high-fat pressurized environment of the tumor.
As a result of the saturation, Intensity's clinical trials have
demonstrated the ability of INT230-6 to kill tumors and elicit an
adaptive immune response within days of injection, representing a
novel approach to cancer cell death that holds the potential to
shift the treatment paradigm and turn many deadly cancers into
chronic diseases. INT230-6 has completed enrollment of over 200
patients in a Phase 1/2 dose escalation trial (NCT03058289) and
Phase 2 randomized control clinical trial in breast cancer (the
INVINCIBLE 2 study) (NCT04781725). The Company is initiating a
Phase 3 trial in soft tissue sarcoma (the INVINCIBLE 3 study)
(NCT06263231), testing INT230-6 as second or third line monotherapy
compared to the standard of care with overall survival as an
endpoint. The Company is also planning a Phase 2/3 program in
presurgical triple-negative breast cancer testing INT230-6 in
combination with standard of care compared to standard of care
alone. For more information about the Company, including
publications, papers and posters about its novel approach to cancer
therapeutics, visit www.intensitytherapeutics.com.
Forward-Looking Statements
Certain statements in this
press release may constitute "forward-looking statements" within
the meaning of the United States Private Securities Litigation
Reform Act of 1995, as amended to date. These statements include,
but are not limited to, statements relating to the development of
the Company's clinical programs. When or if used in this
communication, the words "may," "could," "should," "anticipate,"
"believe," "estimate," "expect," "intend," "plan," "predict" and
similar expressions and their variants, as they relate to the
Company or its management, may identify forward-looking statements.
The forward-looking statements contained in this press release are
based on management's current expectations and projections about
future events, nevertheless, actual results or events could differ
materially from the plans, intentions and expectations disclosed
in, or implied by, the forward-looking statements. These risks and
uncertainties, many of which are beyond our control, include: the
initiation, timing, progress and results of future preclinical
studies and clinical trials and research and development programs;
the need to raise additional funding before the Company can expect
to generate any revenues from product sales; plans to develop and
commercialize product candidates; the timing or likelihood of
regulatory filings and approvals; the ability of the Company's
research to generate and advance additional product candidates; the
implementation of the Company's business model, strategic plans for
the Company's business, product candidates and technology;
commercialization, marketing and manufacturing capabilities and
strategy; the rate and degree of market acceptance and clinical
utility of the Company's system; the Company's competitive
position; the Company's intellectual property position;
developments and projections relating to the Company's competitors
and its industry; the Company's ability to maintain and establish
collaborations or obtain additional funding; expectations related
to the use of cash and cash equivalents and investments; estimates
regarding expenses, future revenue, capital requirements and needs
for additional financing; and other risks described in the section
entitled "Risk Factors" in the Company's SEC filings, which can be
obtained on the SEC website at www.sec.gov. Readers are cautioned
not to place undue reliance on the forward-looking statements,
which speak only as of the date on which they are made and reflect
management's current estimates, projections, expectations and
beliefs. The Company does not plan to update any such
forward-looking statements and expressly disclaims any duty to
update the information contained in this press release except as
required by law.
Investor Relations Contact:
Justin Kulik
Justin@coreir.com
CORE IR
(516) 222-2560
Media Contact:
Jules
Abraham
CORE IR
pr@coreir.com
View original content to download
multimedia:https://www.prnewswire.com/news-releases/intensity-therapeutics-inc-announces-the-appointment-of-thomas-dubin-to-its-board-of-directors-302145873.html
SOURCE Intensity Therapeutics Inc.